Evidence map›Paper›PMID 20705476›Full record

ReviewCritical reviews in oncology/hematology2011

Cellular aging and cancer.

Peter J Hornsby

Abstract readReview
In one paragraph

Review in Critical reviews in oncology/hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Peter J HornsbyDepartment of Physiology and Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX 78245, USA. hornsby@uthscsa.edu
The University of Texas Health Science Center at San Antonio · US

Funding

STUDIES OF THE MRG15 GENE IN CELL CYCLE AND CELL SENESCENCEP01AG020752 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI SMITH, JAMES · 2001 to 2005
$8.5M
TYPE II 3BETA HSD GENE--REGULATION OF DHEAS SYNTHESISR37AG012287 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HORNSBY, PETER J · 1998 to 2009
$2.5M
NIA NIH HHS P01 AG020752NIA NIH HHS R37 AG012287
6 · The paper itself

Abstract

Aging is manifest in a variety of changes over time, including changes at the cellular level. Cellular aging acts primarily as a tumor suppressor mechanism, but also may enhance cancer development under certain circumstances. One important process of cellular aging is oncogene-induced senescence, which acts as a significant anti-cancer mechanism. Cellular senescence resulting from damage caused by activated oncogenes prevents the growth of potentially neoplastic cells. Moreover, cells that have entered senescence appear to be targets for elimination by the innate immune system. In another aspect of cellular aging, the absence of telomerase activity in normal tissues results in such cells lacking a telomere maintenance mechanism. One consequence is that in aging there is an increase in cells with shortened telomeres. In the presence of active oncogenes that cause expansion of a neoplastic clone, shortening of telomeres, leading to telomere dysfunction, prevents the indefinite expansion of the clone, because the cells enter crisis. Crisis results from chromosome fusions and other defects caused by dysfunctional telomeres and is a terminal state of the neoplastic clone. In this way the absence of telomerase in human cells, while one cause of cellular aging, also acts as an anti-cancer mechanism.

Indexed as

Cellular SenescenceAnimalsCell DivisionCell ProliferationCells, CulturedCell Transformation, NeoplasticDNA DamageGene Expression Regulation, DevelopmentalGene Expression Regulation, NeoplasticHumansImmunity, InnateMiceMice, NudeNeoplasmsOncogenesTelomeraseTelomeraseTumor Suppressor Proteins

Identifiers

PMID20705476
PMCPMC3033987
OpenAlexW2031772183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.